{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/influenza-seasonal/management/treating-influenza/","result":{"pageContext":{"chapter":{"id":"9cbc6ee5-b0da-5b46-9ce4-3704f7cf24a9","slug":"treating-influenza","fullItemName":"Scenario: Treating influenza","depth":2,"htmlHeader":"<!-- begin field 51f41bdd-fa45-4814-89b3-bda810959a60 --><h2>Scenario: Treatment of influenza</h2><!-- end field 51f41bdd-fa45-4814-89b3-bda810959a60 -->","summary":"Covers the management of people presenting with influenza-like symptoms.","htmlStringContent":"<!-- begin item 37584bcd-2aa0-4dbb-9554-55b5f381fbf9 --><!-- begin field e8e74cae-0974-4923-bc93-acbc015a6e09 --><p>From birth onwards.</p><!-- end field e8e74cae-0974-4923-bc93-acbc015a6e09 --><!-- end item 37584bcd-2aa0-4dbb-9554-55b5f381fbf9 -->","topic":{"id":"7143131b-dc98-5d14-aef2-f50114a27d13","topicId":"c00149e5-18ab-49c6-8576-089384091df2","topicName":"Influenza - seasonal","slug":"influenza-seasonal","lastRevised":"Last revised in August 2020","chapters":[{"id":"415ca83c-583b-5dd7-8ce7-a67a72325836","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"39d27467-6801-59da-a28b-29a9a1aa848d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7326279e-c8e9-5783-9cb0-433a2e0c5061","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ecde5124-7df2-5d70-921e-cfa13a752476","slug":"changes","fullItemName":"Changes"},{"id":"b4d67dc6-a391-5644-a3a4-89c1c0c49e3f","slug":"update","fullItemName":"Update"}]},{"id":"3b2a94ae-a366-5ff9-8a35-6f8eb63736a1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8b66965c-fc03-5267-ac06-f0edc2bf81ea","slug":"goals","fullItemName":"Goals"},{"id":"32bc1d45-c0ea-55ed-8723-fdbf13b7196e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c5aa9558-010a-5b32-b95a-40f647ef373e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b9c5c598-f72e-505f-b951-cbe710a6af02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d0c6ad8d-5845-5dfd-b2d0-b04bb5395c62","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"48e0bfcd-fd33-552c-b052-28533a176218","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"feb6e56c-e4f6-57f4-bbee-0876089197e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bc17d7e2-a53a-595c-9f57-7080c9814001","slug":"definition","fullItemName":"Definition"},{"id":"d0475ee5-11e2-5ad5-8628-4f513e50236f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0aabed4-a912-518e-9257-8653bc7541e4","slug":"complications","fullItemName":"Complications"}]},{"id":"f81fdd28-028a-5558-92b2-90a1569692bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dcd79bc4-67e6-52b5-af13-ab18772e4c55","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4da6c7b5-c872-551a-aff9-100bef3041ca","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b540d9e5-48f5-5b1c-a8b1-8a37d951449f","fullItemName":"Management","slug":"management","subChapters":[{"id":"9cbc6ee5-b0da-5b46-9ce4-3704f7cf24a9","slug":"treating-influenza","fullItemName":"Scenario: Treating influenza"},{"id":"b82606d4-79c4-5b96-84cd-115c371c80b4","slug":"post-exposure-prophylaxis","fullItemName":"Scenario: Post-exposure prophylaxis"}]},{"id":"267c67be-5fb6-510f-b3f7-15ece61003d9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"418c695e-c703-5e30-9ec2-9bf2afeb6001","slug":"oseltamivir","fullItemName":"Oseltamivir"},{"id":"370b7394-2bad-5d4f-ac2a-06de67bbefea","slug":"zanamivir","fullItemName":"Zanamivir"}]},{"id":"83f51ef5-d6f9-5101-849d-c72bd5975126","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fe85159c-da36-5171-9b52-88d8edd9ee77","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"46f280be-d769-501b-905f-789bbf2d8454","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9904923d-c7de-53aa-8253-15c9392ece2e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3790de44-d79a-5486-b053-d09c6dccc2cc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e631b66-3030-5dd0-97e7-7504198b5a14","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ab624014-37fa-5613-976c-e2ffa65a7e90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b4d3fc-b6de-5df4-ad98-bf9ea439e342","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b540d9e5-48f5-5b1c-a8b1-8a37d951449f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"1e5e415e-9a6c-50ed-b20b-8f2de5428d8a","slug":"when-to-prescribe-antivirals","fullItemName":"When to prescribe antivirals","depth":3,"htmlHeader":"<!-- begin field 499bab9a-b783-4ee1-b7d2-3c84fd40d252 --><h3>When should I prescribe an antiviral drug for someone with influenza?</h3><!-- end field 499bab9a-b783-4ee1-b7d2-3c84fd40d252 -->","summary":null,"htmlStringContent":"<!-- begin item 483d409f-c484-43b7-a6ce-42bd620d521c --><!-- begin field f8a80619-2bce-4181-930e-4368bc859a95 --><ul><li><strong>Prescribe an antiviral drug (oral oseltamivir or inhaled zanamivir) for people with influenza if <em>all</em> of the following apply: </strong><ul><li>The national surveillance scheme indicates that influenza is circulating.</li><li>The person is in an <a class=\"topic-reference internal-reference\" href=\"/topics/influenza-seasonal/management/treating-influenza/#at-risk-groups\">&#39;at risk&#39; group</a> of people who are likely to suffer a worse prognosis from influenza than otherwise healthy people.</li><li>The person can start treatment within 48 hours of the onset of symptoms (36 hours in the case of zanamivir in children).<ul><li>Starting treatment after 48 hours of the onset of symptoms (or 36 hours in the case of zanamivir in children) is an off-label use and clinical judgement should be exercised. </li></ul></li></ul></li><li><strong>Consider prescribing oral oseltamivir for previously healthy people with influenza if all of the following apply:</strong><ul><li>The person is not in an 'at risk' group, but it is felt that they are at serious risk of developing complications.</li><li>The national surveillance scheme indicates that influenza is circulating. </li><li>The person is able to start treatment within 48 hours of the onset of symptoms. </li></ul></li></ul><!-- end field f8a80619-2bce-4181-930e-4368bc859a95 --><!-- end item 483d409f-c484-43b7-a6ce-42bd620d521c -->","subChapters":[{"id":"d8ab6442-591f-55ea-af48-cebc0543af06","slug":"at-risk-groups","fullItemName":"'At risk' groups","depth":4,"htmlHeader":"<!-- begin field 8154838e-f1a4-42ba-a58c-dd410de48b24 --><h4>'At risk' groups</h4><!-- end field 8154838e-f1a4-42ba-a58c-dd410de48b24 -->","summary":null,"htmlStringContent":"<!-- begin item 6890a333-9b58-4256-86ef-2e6d281d575a --><!-- begin field e9bf4d76-4d0f-430b-ad40-f472ab0491ea --><ul><li><strong>'At risk group' includes people aged over 65 years, children aged under 6 months, pregnant women (at any stage of pregnancy, or women up to two weeks post partum), and people with any of the following conditions:</strong><ul><li><strong>Asplenia or dysfunction of the spleen</strong> — including conditions such as homozygous sickle cell disease and coeliac syndrome that may lead to splenic dysfunction. </li><li><strong>Chronic respiratory disease</strong>, including:<ul><li>Chronic obstructive pulmonary disease, chronic bronchitis and emphysema, bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis, and bronchopulmonary dysplasia. </li><li>Asthma that requires continuous or repeated use of inhaled or systemic corticosteroids or with previous exacerbations requiring hospital admission.</li><li>Children who have previously been admitted to hospital for lower respiratory tract disease.</li></ul></li><li><strong>Chronic heart disease </strong>— including congenital heart disease, hypertension with cardiac complications, chronic heart failure, and individuals requiring regular medication or follow up for ischaemic heart disease.</li><li><strong>Chronic kidney disease </strong>— including chronic kidney disease stage 3, 4 or 5, chronic kidney failure, nephrotic syndrome, and kidney transplantation. </li><li><strong>Chronic liver disease</strong>, including cirrhosis, biliary atresia, and chronic hepatitis.</li><li><strong>Chronic neurological conditions</strong>, including stroke and transient ischaemic attack. Conditions in which respiratory function may be compromised (for example, polio syndrome). Individual assessment should also be considered in clinically vulnerable individuals including those with cerebral palsy, learning disabilities, multiple sclerosis and related or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability. </li><li><strong>Diabetes mellitus</strong>, including type 1 diabetes and type 2 diabetes (requiring oral hypoglycaemic drugs or a controlled diet).</li><li><strong>Immunosuppression </strong>due to disease or treatment, including: <ul><li>People undergoing chemotherapy (or radiotherapy) leading to immunosuppression.</li><li>People undergoing bone marrow transplant.</li><li>HIV infection (all stages).</li><li>Individuals treated with, or likely to be treated with, systemic steroids for more than 1 month at dosages equivalent to prednisolone 20 mg or more daily (at any age) or, for children weighing less than 20 kg, a dose of 1 mg or more per kg body weight per day.</li><li>Multiple myeloma. </li><li>Genetic disorders affecting the immune system (for example, IRAK-4, NEMO, complement disorder). </li></ul></li><li><strong>Morbid obesity (body mass index of 40 or more).</strong></li></ul></li></ul><!-- end field e9bf4d76-4d0f-430b-ad40-f472ab0491ea --><!-- end item 6890a333-9b58-4256-86ef-2e6d281d575a -->","subChapters":[]},{"id":"af1e1a09-db6c-54bb-8d14-f3ec39678842","slug":"basis-for-recommendation-b36","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a979b87b-35dc-43ea-8036-142d6eea32cc --><h4>Basis for recommendation</h4><!-- end field a979b87b-35dc-43ea-8036-142d6eea32cc -->","summary":null,"htmlStringContent":"<!-- begin item b364de60-116d-4526-b2da-7fb2e94ea72a --><!-- begin field 9e814d74-50c4-456c-92ee-bef13b076513 --><p>These recommendations are based on the Public Health England (PHE) <em>PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>], <em>The use of antivirals for the treatment and prophylaxis of influenza: PHE summary of current guidance for healthcare professionals </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2014</a>], the chapter on <em>Influenza </em>in the 'Green Book' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2018a</a>], the National Institute for Health and Care Excellence (NICE) technology appraisal <em>Amantadine, oseltamivir and zanamivir for the treatment of influenza</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">NICE, 2014a</a>], and the manufacturers' Summaries of Product Characteristics for oseltamivir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2019</a>] and zanamivir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">ABPI, 2018</a>]. </p><h5>Efficacy of antivirals in treating influenza virus</h5><ul><li>PHE states that it continues to support the early use of antivirals for people with proven or suspected seasonal influenza who are in high-risk groups or who are considerably unwell (even if not in a high-risk group), as there is good evidence that antivirals can reduce the risk of death in people hospitalised with influenza, and so it is important that severely unwell people are prescribed them appropriately [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2014</a>].</li><li>A Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Jefferson, 2014</a>] which assessed the the potential benefits and harms of neuraminidase inhibitors (NAIs) for preventing and treating influenza in all age group found that:<ul><li>Oseltamivir and zanamivir have small, non-specific effects on reducing the time to alleviation of influenza symptoms in adults, but not in asthmatic children — oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours (95% confidence interval (CI) 8.4 to 25.1 hours, P < 0.0001); zanamivir reduced the time to first alleviation of symptoms in adults by 0.60 days (95% CI 0.39 to 0.81 days, P < 0.00001).</li><li>Treatment of adults with oseltamivir had no significant effect on hospitalisations — risk difference (RD) 0.15% (95% CI -0.78 to 0.91).</li><li>Using either drug as prophylaxis reduces the risk of developing symptomatic influenza. In prophylaxis trials, oseltamivir and zanamivir reduced the risk of symptomatic influenza in:<ul><li>Individuals — oseltamivir: RD 3.05% (95% CI 1.83 to 3.88); number needed to benefit (NNTB) = 33 (26 to 55). Zanamivir: RD 1.98% (95% CI 0.98 to 2.54); NNTB = 51 (40 to 103). </li><li>Households — oseltamivir: RD 13.6% (95% CI 9.52 to 15.47); NNTB = 7 (6 to 11). Zanamivir: RD 14.84% (95% CI 12.18 to 16.55); NNTB = 7 (7 to 9).</li></ul></li><li>Oseltamivir increases the risk of adverse effects, such as nausea, vomiting, psychiatric effects and renal events in adults and vomiting in children — oseltamivir in the treatment of adults increased the risk of nausea (RD 3.66%, 95% CI 0.90 to 7.39); number needed to treat to harm (NNTH) = 28 (95% CI 14 to 112) and vomiting (RD 4.56%, 95% CI 2.39 to 7.58); NNTH = 22 (14 to 42).</li></ul></li><li>However, in response to the review, PHE commented that while it had been suggested that 'antivirals are not effective for influenza', they had the following concerns regarding the evidence presented including [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2014</a>]:   <ul><li>The variation in outcomes, patient groups, and settings studied limits the conclusions of the review.</li><li>The review included evidence only from randomised controlled trials (RCTs), which were carried out in an otherwise healthy population in the community setting (and therefore interpreted the modest effects that NAIs on the duration of acute symptoms in uncomplicated infection). It had limitations in understanding hospitalisations, complications, and the prevention of complications occurring in cases of severe infection, and mortality.</li><li>There was no evidence from RCTs for non-seasonal influenza viruses with high case fatality rates, or a novel influenza virus with pandemic potential, or RCTs in severely ill people (due to ethical considerations).</li><li>In the absence of appropriate RCT data on severe influenza, observational studies have important contributions to make to policy development.</li><li>A substantial volume of observational data was not considered in the review, including evidence of the ability of NAIs to stop the progression of severe cases of H5N1 or pandemic H1N1 infection.</li></ul></li><li>A subsequent National Institute for Health Research (NIHR) health technology assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">NIHR, 2016</a>] reached similar conclusions to the Cochrane review: <ul><li>Oseltamivir and zanamivir cause small reductions in the time to alleviation of influenza symptoms in adults, but not in asthmatic children.</li><li>The use of oseltamivir increases the risk of nausea, vomiting and psychiatric events in adults and vomiting in children and may reduce risk of diarrhoea and cardiac events in adults.</li><li>Observational studies fail to show that oseltamivir has a protective effect on mortality among people with 2009A/H1N1 influenza.</li><li>Prophylaxis with either oseltamivir or zanamivir may reduce symptomatic influenza in individuals and in households but there was no reduction in all other influenza outcomes, including overall influenza-like illness reported as an adverse event on-treatment.</li><li>However, the results did not discount a potential benefit of using zanamivir and oseltamivir in individuals under particular situations, for example in immunocompromised or in compassionate cases, for which few other therapeutic options may exist.</li></ul></li><li>PHE advises that it is essential that physicians treating severely unwell people in any setting are not deterred from prescribing NAIs as a result of confusion over efficacy, and that this is especially true for people hospitalised with proven or suspected influenza [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2014</a>]. </li></ul><!-- end field 9e814d74-50c4-456c-92ee-bef13b076513 --><!-- end item b364de60-116d-4526-b2da-7fb2e94ea72a -->","subChapters":[]}]},{"id":"c91a58fb-4233-5ce2-a2e9-4e6f55332579","slug":"which-antiviral-to-prescribe","fullItemName":"Which antiviral to prescribe","depth":3,"htmlHeader":"<!-- begin field c2851910-7ddb-4f0c-be1a-354b3a5fbb85 --><h3>Which antiviral drug should I prescribe if treatment is indicated?</h3><!-- end field c2851910-7ddb-4f0c-be1a-354b3a5fbb85 -->","summary":null,"htmlStringContent":"<!-- begin item cfe659d7-0a23-41e1-bfc3-7351b2117a1b --><!-- begin field d137ad47-ac88-4111-8c0c-c2c2ee3bdc2a --><ul><li><strong>For uncomplicated influenza in people: </strong><ul><li>Who were previously healthy<strong> </strong>— no antiviral treatment is normally indicated, unless the person is at serious risk of developing serious complications from influenza, then prescribe oral oseltamivir.</li><li>Who are in an at risk group (including women who are pregnant), but <em>are not</em> severely immunosuppressed — prescribe oral oseltamivir. Do not wait for laboratory confirmation. </li><li>Who are severely immunosuppressed, and the dominant strain has:  <ul><li>A lower risk of oseltamivir resistance (for example, A[H3N2] influenza B) — prescribe oral oseltamivir.</li><li>A higher risk of oseltamivir resistance (for example, A [H1N1]) — prescribe inhaled zanamivir, or if this is unsuitable or inappropriate, prescribe oral oseltamivir and follow up.</li></ul></li></ul></li><li><strong>For complicated influenza in people: </strong><ul><li>Who <em>are not</em> severely immunosuppressed — prescribe oral oseltamivir (or oseltamivir via a nasogastric tube if appropriate) first line.<ul><li>Prescribe inhaled zanamivir (or it can be administered via a nebuliser, or intravenously if required) second line. </li></ul></li><li>Who <em>are</em> severely immunosuppressed and the dominant strain has:  <ul><li>A lower risk of oseltamivir resistance (for example, A[H3N2] influenza B) — prescribe oral oseltamivir (or oseltamivir via a nasogastric tube if appropriate) first line. Prescribe inhaled zanamivir (or it can be administered via a nebuliser, or intravenously if required) second line. </li><li>A higher risk of oseltamivir resistance (for example, A [H1N1]) — prescribe inhaled zanamivir (or it can be administered via a nebuliser, or intravenously if required). If there are delays in obtaining aqueous zanamivir, use oseltamivir as a bridging treatment until zanamivir is available.</li></ul></li></ul></li><li>See the <a class=\"topic-reference internal-reference\" href=\"/topics/influenza-seasonal/prescribing-information/\">prescribing information</a> sections on Oseltamivir and Zanamivir for recommended doses, contraindications, cautions, and possible adverse effects of these drugs.</li></ul><!-- end field d137ad47-ac88-4111-8c0c-c2c2ee3bdc2a --><!-- end item cfe659d7-0a23-41e1-bfc3-7351b2117a1b -->","subChapters":[{"id":"2780d163-8b2f-5192-9a6e-f49af26cafbb","slug":"basis-for-recommendation-648","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 85d90220-7573-429a-8aa0-23189a215efd --><h4>Basis for recommendation</h4><!-- end field 85d90220-7573-429a-8aa0-23189a215efd -->","summary":null,"htmlStringContent":"<!-- begin item 6483de89-3177-4b28-a05a-eaec83611a8f --><!-- begin field 8f045bbb-75e6-45b1-a620-c110db0bce32 --><p>These recommendations are based on the Public Health England (PHE) <em>PHE</em><em><em> </em>guidance on use of antiviral agents for the treatment and prophylaxis of influenza </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>], and the National Institute for Health and Care Excellence (NICE) technology appraisal <em>Amantadine, oseltamivir and zanamivir for the treatment of influenza </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">NICE, 2014a</a>]. </p><h5>Choice of oseltamivir or zanamivir [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>]</h5><ul><li>Some influenza subtypes are associated with a greater risk of developing oseltamivir resistance. This risk is greatest in people who are severely immunosuppressed. The selection of first line antivirals in these people should take account the subtype of influenza causing infection, or if that is unknown, the dominant strain of influenza that is circulating during the current influenza season.</li><li>Influenza A (H1N1) is considered to be a higher risk for the development of oseltamivir resistance, while influenza A(H3N2) and influenza B are considered lower risk. </li><li>The dominant circulating strain of influenza is obtainable from the PHE weekly <a href=\"http://www.gov.uk/government/statistics/weekly-national-flu-reports\" data-hyperlink-id=\"8f1fc3b6-a2d4-49be-9507-aa2201023b17\">influenza reports</a>. </li></ul><h5>Unlicensed zanamivir</h5><ul><li><p>Zanamivir solution for IV or nebulised administration is an unlicensed medication and is available on a compassionate use basis for named patients in the UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>]. </p></li></ul><!-- end field 8f045bbb-75e6-45b1-a620-c110db0bce32 --><!-- end item 6483de89-3177-4b28-a05a-eaec83611a8f -->","subChapters":[]}]},{"id":"a10e873b-fc7c-5450-aacc-a653a4fc16fb","slug":"advice-for-people-with-influenza","fullItemName":"Advice for people with influenza","depth":3,"htmlHeader":"<!-- begin field 7f08f95d-1098-499c-b09a-891629799ed5 --><h3>What advice should I give someone to help manage influenza?</h3><!-- end field 7f08f95d-1098-499c-b09a-891629799ed5 -->","summary":null,"htmlStringContent":"<!-- begin item ff5e55e4-c4ec-4ecd-8721-70f40f01f1b7 --><!-- begin field 197b715c-7828-409a-912e-7a6fb10f7bb4 --><ul><li><strong>Advise the person:</strong><ul><li>To drink adequate fluids to avoid dehydration. </li><li>To take paracetamol or ibuprofen for symptomatic relief. </li><li>To rest in bed if they feel fatigued.</li><li>To stay off work or school if they feel unable to attend — for most people, about 1 week will be adequate.</li><li>That fever and associated systemic symptoms of uncomplicated influenza usually resolve after about 1 week, although some symptoms (such as cough and fatigue) may persist for up to 2 weeks after resolution of fever.</li><li>About the symptoms of complicated influenza and to seek medical advice should their condition deteriorate. </li></ul></li><li><strong>Advise the person that routine follow up is not necessary, but they should:</strong><ul><li>Seek urgent medical attention if they develop shortness of breath or pleuritic chest pain, or if they start to cough up blood (haemoptysis) — this may indicate the development of pneumonia secondary to bacterial superinfection. </li><li>Arrange a follow-up appointment if there is no improvement after 1 week (that is, they are still significantly ill), or they are deteriorating.</li><li>Have a lower threshold for seeking help if they are caring for a young child or baby with influenza.</li></ul></li></ul><!-- end field 197b715c-7828-409a-912e-7a6fb10f7bb4 --><!-- end item ff5e55e4-c4ec-4ecd-8721-70f40f01f1b7 -->","subChapters":[{"id":"9b69b083-5bc6-5d65-8090-9a2b2919bf0a","slug":"basis-for-recommendation-2e9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 64f8e222-206e-47d6-8024-4dd6d02150ad --><h4>Basis for recommendation</h4><!-- end field 64f8e222-206e-47d6-8024-4dd6d02150ad -->","summary":null,"htmlStringContent":"<!-- begin item 2e924e9b-bfba-4a0c-ba56-9e8b18a54295 --><!-- begin field 6c746091-8572-45f2-9768-cf6f95b9311b --><p>These recommendations are based on the British Medical Journal (BMJ) best practice guide <em>Influenza infection </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">BMJ, 2019</a>], the Public Health England (PHE) <em>PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>], expert opinion in a narrative review <em>Influenza</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Paules, 2017</a>], and what CKS considers good medical practice. </p><h5>Self-care advice</h5><ul><li>It is universally recommended that adequate fluid intake should be maintained when symptoms of influenza are present, to replace fluid lost by fever, sweating, and nasal discharge. However, a Cochrane systematic review found no controlled trials assessing the effect of increasing fluid intake in people with acute respiratory infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Guppy et al, 2011</a>]. </li><li>Paracetamol and ibuprofen are recommended for the symptomatic relief of influenza on the basis that they reduce fever and pain (including headache and myalgia).<ul><li>The antipyretic and analgesic efficacy of paracetamol and ibuprofen have been confirmed by RCTs in several conditions, including influenza and the common cold [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Eccles, 2006</a>].</li></ul></li><li>Many people with influenza feel ill and fatigued to the extent that they voluntarily take to their beds [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Jennings and Read, 2005</a>], and this should be encouraged. </li><li>There are no formal guidelines as to how long a person should stay off work or school, but prognostic data from the placebo arms of controlled trials indicate that most people should feel sufficiently well to return to normal activities after 1 week at most [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Burch et al, 2008</a>].</li></ul><h5>Advice about when to seek medical attention</h5><ul><li>CKS identified no reviews or guidelines on when it is appropriate to follow up a person with influenza. These recommendations are what CKS considers to be good clinical practice.<ul><li>Shortness of breath, pain on breathing, and haemoptysis may indicate the development of pneumonia secondary to bacterial superinfection. Secondary bacterial pneumonia is an important complication of influenza and contributes to approximately 25% of all influenza-associated deaths [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">BMJ, 2019</a>].  <ul><li>The most common bacteria are <em>Streptococcus pneumoniae</em>, <em>Staphylococcus aureus</em>, and <em>Haemophilus influenzae</em>.</li></ul></li><li>The natural history of influenza indicates that symptoms should be improving after 1 week [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Paules, 2017</a>]. If symptoms are not improving or are worsening, reassessment of the diagnosis should be considered.</li><li>Children are at high risk of developing complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">BMJ, 2019</a>] and there is an increased risk of hospital admission in children younger than 5 years (particularly children aged less than 2 years) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Paules, 2017</a>]. </li></ul></li></ul><!-- end field 6c746091-8572-45f2-9768-cf6f95b9311b --><!-- end item 2e924e9b-bfba-4a0c-ba56-9e8b18a54295 -->","subChapters":[]}]},{"id":"d979f299-33bf-50ef-9c35-629e6d097f0e","slug":"follow-up-admission","fullItemName":"Follow up and admission","depth":3,"htmlHeader":"<!-- begin field d7aa97d7-55fb-44f6-803a-f7a9d9c8769b --><h3>When should I follow up or admit a person with influenza?</h3><!-- end field d7aa97d7-55fb-44f6-803a-f7a9d9c8769b -->","summary":null,"htmlStringContent":"<!-- begin item a1fd2ed2-c4d8-4459-8611-9e3168b5636d --><!-- begin field e6b2c8df-3e61-44de-91a7-e9acdcabecf3 --><ul><li><strong>Consider follow up</strong> <strong>particularly in people at high risk of serious complications (for example, people aged over 65 years) within 1 week, to confirm that symptoms are improving and to exclude the development of secondary complications.</strong></li><li><strong>Consider admission to hospital, depending on clinical judgement, if: </strong><ul><li>A <a class=\"topic-reference internal-reference\" href=\"/topics/influenza-seasonal/background-information/complications/\">complication</a> of influenza occurs.<ul><li>Pneumonia is a common complication that may be indicated by lower respiratory tract distress (characterized by laboured breathing, shortness of breath, pleuritic chest pain, and haemoptysis). It may occur immediately, or up to 2 weeks, after initial symptoms of influenza. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/chest-infections-adult/\">Chest infections - adult</a> and <a class=\"topic-reference external-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/\">Cough - acute with chest signs in children</a>.</li></ul></li><li>The person has a co-existing medical condition that puts them at high risk of complications — for example, people with diabetes mellitus (particularly type 1) are at risk of hyperglycaemia, ketoacidosis, and diabetic coma.</li><li>An <a class=\"topic-reference internal-reference\" href=\"/topics/influenza-seasonal/diagnosis/differential-diagnosis/\">alternative diagnosis</a> is suspected.</li></ul></li><li><strong>Also consider admission to hospital in children:</strong><ul><li>Aged under 2 years if they are in an <a class=\"topic-reference internal-reference\" href=\"/topics/influenza-seasonal/management/treating-influenza/#at-risk-groups\">&#39;at risk&#39; group</a>.</li><li>If they have febrile symptoms that may indicate serious illness. For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/feverish-children-risk-assessment/\">Feverish children - risk assessment</a>.</li></ul></li></ul><!-- end field e6b2c8df-3e61-44de-91a7-e9acdcabecf3 --><!-- end item a1fd2ed2-c4d8-4459-8611-9e3168b5636d -->","subChapters":[{"id":"a7d3ff15-a747-5cb9-ae18-3bab77173154","slug":"basis-for-recommendation-ae7","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 19abc98f-7f04-4c80-9478-e4aaec7f2ae8 --><h4>Basis for recommendation</h4><!-- end field 19abc98f-7f04-4c80-9478-e4aaec7f2ae8 -->","summary":null,"htmlStringContent":"<!-- begin item ae730a22-07c0-4e5d-9500-243600567e49 --><!-- begin field e7951e30-924a-46fa-88f4-cd2991d5ea9c --><p>These recommendations are based on the British Medical Journal (BMJ) best practice guide <em>Influenza infection </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">BMJ, 2019</a>], the Public Health England (PHE) <em>PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>], expert opinion in a narrative review <em>Influenza</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Paules, 2017</a>], and what CKS considers good medical practice. </p><h5>Follow up</h5><ul><li>CKS identified no reviews or guidelines on when it is appropriate to follow up a person with influenza. Therefore, these recommendations reflect what CKS considers to be good clinical practice.<ul><li>The recommendation to consider follow-up in people who are at high risk of complications is pragmatic. The natural history of influenza indicates that symptoms should be improving after 1 week [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">BMJ, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Paules, 2017</a>]. If symptoms are not improving or are worsening, reassessment of the diagnosis should be considered. </li></ul></li></ul><h5>Admission</h5><ul><li>CKS identified no reviews or guidelines on when it is appropriate to admit a person with influenza. Therefore, these recommendations reflect what CKS considers to be good clinical practice.<ul><li>Development of complications — the recommendation to consider admitting people with complications of influenza (depending on clinical judgment) is pragmatic as these people may require specialist assessment and management.<ul><li>PHE states that all people with complicated influenza should receive treatment and that this will often be in hospital [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>]. </li><li>Pneumonia is the most common serious complication of influenza. It may be caused by the influenza virus itself, or by bacterial superinfection with <em>Streptococcus pneumoniae</em>, <em>Staphylococcus aureus</em>, or <em>Haemophilus influenzae</em>. Pneumonia should be regarded as a serious condition which will usually require specialist assessment and management. Bacterial pneumonia is the main cause of mortality in people who are hospitalized with influenza [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Jennings and Read, 2005</a>].</li></ul></li><li>The presence of medical comorbidities (for example, neuromuscular disease, cognitive dysfunction, pulmonary disease, cardiovascular disease, renal disease, liver disease, diabetes mellitus, heavy alcohol use, and obesity) is associated with an increased risk of mortality from influenza [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Paules, 2017</a>] — people with diabetes mellitus are known to be at increased risk of bacterial pneumonia and acute complications of diabetes (such as ketoacidosis) after infection with influenza [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Joshi et al, 1999</a>]. The incidence of ketoacidosis in people with diabetes has been observed to increase by 50% in influenza epidemic years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Bouter et al, 1991</a>].</li><li>Alternative diagnosis — other serious illnesses may have signs and symptoms that mimic influenza. People with these symptoms should be seen by a specialist if there is diagnostic doubt.</li><li>Children are at high risk of developing complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">BMJ, 2019</a>] and there is an increased risk of hospital admission in children younger than 5 years (particularly children aged less than 2 years) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Paules, 2017</a>].   </li></ul></li></ul><!-- end field e7951e30-924a-46fa-88f4-cd2991d5ea9c --><!-- end item ae730a22-07c0-4e5d-9500-243600567e49 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}